| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 1/6 |
Life Science REIT plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.39 |
| 52 Week High | UK£0.77 |
| 52 Week Low | UK£0.37 |
| Beta | 0.13 |
| 1 Month Change | -4.89% |
| 3 Month Change | -35.17% |
| 1 Year Change | -41.24% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -61.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| LABS | GB Health Care REITs | GB Market | |
|---|---|---|---|
| 7D | 1.8% | -0.06% | 2.2% |
| 1Y | -41.2% | -14.6% | 0.9% |
Price Volatility
| LABS volatility | |
|---|---|
| LABS Average Weekly Movement | 4.0% |
| Health Care REITs Industry Average Movement | 2.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Volatility Over Time: LABS's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Simon Farnsworth | www.lifesciencereit.co.uk |
Life Science REIT plc Fundamentals Summary
| LABS fundamental statistics | |
|---|---|
| Market cap | UK£136.15m |
| Earnings (TTM) | -UK£21.71m |
| Revenue (TTM) | UK£19.94m |
6.8x
P/S Ratio-6.3x
P/E RatioIs LABS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LABS income statement (TTM) | |
|---|---|
| Revenue | UK£19.94m |
| Cost of Revenue | UK£6.12m |
| Gross Profit | UK£13.83m |
| Other Expenses | UK£35.53m |
| Earnings | -UK£21.71m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.062 |
| Gross Margin | 69.33% |
| Net Profit Margin | -108.85% |
| Debt/Equity Ratio | 38.0% |
How did LABS perform over the long term?
See historical performance and comparison